Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021

Publisher Name :
Date: 05-Apr-2017
No. of pages: 70
Price : Single User: US $ 3500  US $ 2500 Corporate User: US $ 5000  US $ 4000
Inquire Before Buying
Avail $1000 Discount on this report till 30 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

HCM is the enlargement of the heart muscle (myocardium), which disrupts the functions of the heart. HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any age group. Hypertrophy is defined as an enlargement of a tissue or organ, and cardiomyopathy refers to diseases related to heart muscles. Therefore, HCM is defined as a condition, which is characterized by abnormal thickening of heart muscles, which makes pumping of blood from the heart to various organs difficult. Therefore, the heart must induce more pressure to pump blood to various vital organs.

The analysts forecast global hypertrophic cardiomyopathy therapeutics market to grow at a CAGR of 1.80% during the period 2017-2021.

Covered in this report

This report covers the present scenario and the growth prospects of the global hypertrophic cardiomyopathy therapeutics market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:


  • Americas

  • APAC

  • EMEA


The report, Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors


  • AstraZeneca

  • Merck

  • Pfizer

  • Sanofi


Other prominent vendors


  • Gilead Sciences

  • Novartis

  • Teva Pharmaceutical Industries


Market driver


  • Adoption of sedentary lifestyle.

  • For a full, detailed list, view our report


Market challenge


  • Technological advances in devices.

  • For a full, detailed list, view our report


Market trend


  • Development of translational bioinformatics (TBI).

  • For a full, detailed list, view our report


Key questions answered in this report


  • What will the market size be in 2021 and what will the growth rate be?

  • What are the key market trends?

  • What is driving this market?

  • What are the challenges to market growth?

  • Who are the key vendors in this market space?

  • What are the market opportunities and threats faced by the key vendors?

  • What are the strengths and weaknesses of the key vendors?

Avail $1000 Discount on this report till 30 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
Key market highlights

PART 05: Disease overview
Disease overview

PART 06: Key clinical trials

PART 07: Market dynamics

PART 08: Market landscape
Market overview
Five forces analysis

PART 09: Market segmentation by drug-class
Global calcium channel blockers market
Global beta-adrenergic blockers market
Global antiarrhythmic market
Global anticoagulants market

PART 10: Geographical segmentation
HCM therapeutics market in Americas
HCM therapeutics market in EMEA
HCM therapeutics market in APAC

PART 11: Decision framework

PART 12: Drivers and challenges
Market drivers
Market challenges
Impact of drivers and challenges on key customer segments (hospitals and pharmacies)

PART 13: Market trends
Increasing availability of genetic tests
Development of TBI
Advent of genomic medicine

PART 14: Vendor landscape
Competitive landscape

PART 15: Key vendor analysis
AstraZeneca
Merck
Pfizer
Sanofi
Other prominent vendors

PART 16: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Types of HCM
Exhibit 02: Treatment for HCM
Exhibit 03: Snapshot of HCM therapeutics pipeline 2016
Exhibit 04: Pipeline analysis for HCM therapeutics market
Exhibit 05: Mutation
Exhibit 06: Identification of pathogenicity in genes by genetic testing
Exhibit 07: Global HCM therapeutics market snapshot
Exhibit 08: Global HCM therapeutics market 2016-2021 ($ millions)
Exhibit 09: Opportunity analysis in global HCM therapeutics market
Exhibit 10: Five forces analysis
Exhibit 11: Market segmentation based on drug class
Exhibit 12: Global calcium channel blockers market 2016-2021 ($ millions)
Exhibit 13: Global beta-adrenergic blockers market 2016-2021 ($ millions)
Exhibit 14: Global antiarrhythmic market 2016-2021 ($ millions)
Exhibit 15: Global anticoagulants market 2016-2021 ($ millions)
Exhibit 16: Global HCM therapeutics market by geography 2016 and 2021
Exhibit 17: Global HCM therapeutics market by geography 2016-2021 ($ millions)
Exhibit 18: Market scenario in Americas
Exhibit 19: HCM therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 20: Market scenario in EMEA
Exhibit 21: HCM therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 22: Market scenario in APAC
Exhibit 23: HCM therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 24: Prevalence of obesity among US adults 2015
Exhibit 25: Impact of drivers and challenges
Exhibit 26: Group of HCM individuals based on genetic tests
Exhibit 27: Competitive structure analysis of global HCM therapeutics market 2016
Exhibit 28: AstraZeneca: Key highlights
Exhibit 29: AstraZeneca: Strength assessment
Exhibit 30: AstraZeneca: Strategy assessment
Exhibit 31: AstraZeneca: Opportunity assessment
Exhibit 32: Merck: Key highlights
Exhibit 33: Merck: Strength assessment
Exhibit 34: Merck: Strategy assessment
Exhibit 35: Merck: Opportunity assessment
Exhibit 36: Pfizer: Key highlights
Exhibit 37: Pfizer: Strength assessment
Exhibit 38: Pfizer: Strategy assessment
Exhibit 39: Pfizer: Opportunity assessment
Exhibit 40: Sanofi: Key highlights
Exhibit 41: Sanofi: Strength assessment
Exhibit 42: Sanofi: Strategy assessment
Exhibit 43: Sanofi: Opportunity assessment

  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 35
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2017, provides an overview of the Organophosphate and Carbamate Poisoning (Toxicology) pipeline landscape.Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and som......
  • Behcet Disease - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 65
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Pipeline Review, H1 2017, provides an overview of the Behcet Disease (Cardiovascular) pipeline landscape.Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals (sex organs). More serious symptoms can include inflammation (swelling, h......
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 64
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2017, provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline landscape.Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headach......
  • Post Menopausal Osteoporosis - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 73
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H1 2017, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone stru......
  • Pompe Disease - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 52
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pompe Disease - Pipeline Review, H1 2017, provides an overview of the Pompe Disease (Metabolic Disorders) pipeline landscape.Pompe disease is an inherited disorder caused by defect in a gene called GAA. The GAA gene is responsible for the production of the GAA enzyme (acid alpha-glucosidase). This enzyme is needed to break down glycogen, a form of sugar stored in muscle cells. When too much glycogen builds up ......
  • Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017, provides an overview of the Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline landscape.Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wri......
  • LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists - Pipeline Insights, 2017
    Published: 12-May-2017        Price: US 1250 Onwards        Pages: 57
    DelveInsight's, "LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists-Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. This report provides information on the therapeutic development based on the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists dealing with all the pipeline......
  • Radiation Toxicity - Pipeline Review, H1 2017
    Published: 09-May-2017        Price: US 2000 Onwards        Pages: 202
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity - Pipeline Review, H1 2017, provides an overview of the Radiation Toxicity (Toxicology) pipeline landscape.Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal ......
  • Guillain-Barre Syndrome - Pipeline Review, H1 2017
    Published: 09-May-2017        Price: US 2000 Onwards        Pages: 46
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome - Pipeline Review, H1 2017, provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape.Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the symmetrica......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs